The global autoimmune market is driven by the rising popularity of biologics in the pharma market. Biologics are being increasingly used to treat autoimmune diseases at the molecular level. Another factor driving the growth of the global autoimmune market is the growing need for novel products for a range of indicators. However, the high cost of drugs will inhibit the growth of this market. In addition to this, a lack of effective diagnostics for autoimmune diseases and also the high complexity level for the treatment of autoimmune diseases are posing a challenge.
The market is likely to face intense competition on account of new product releases, new applications of the products and services, and product extensions. Regionally, North America is expected to continue its dominance for the coming years on account of the healthcare reforms, favorable reimbursement policies, use of latest technology, and improved healthcare infrastructure. Leading companies operating in the global autoimmune market are: Johnson & Johnson, AbbVie, Biogen, Pfizer, Amgen, and F. Hoffmann-La Roche